Residency · Residency · Hematology Thrombosis

Anticoagulant Pharmacology - DOACs and Heparins

Introduction

Anticoagulant therapy is a cornerstone of hematology practice, forming the basis of treatment and prevention for venous thromboembolism, stroke prevention in atrial fibrillation, management of mechanical heart valves, and a host of other thrombotic conditions. The therapeutic landscape has been transformed over the past two decades by the introduction of direct oral anticoagulants (DOACs), which have supplanted warfarin as the first-line anticoagulant for most indications. Nevertheless, heparin-based anticoagulants remain indispensable in the acute care setting, and warfarin retains specific indications where DOACs are either inferior or contraindicated. A thorough understanding of the pharmacokinetics, pharmacodynamics, drug interactions, monitoring strategies, and reversal options for each class of anticoagulant is essential for safe and effective prescribing.

Heparins

Unfractionated Heparin (UFH)

Unfractionated heparin is a heterogeneous mixture of sulfated glycosaminoglycan chains ranging in molecular weight from 3,000 to 30,000 daltons (mean approximately 12,000 to 15,000 daltons). Its mechanism of action centers on its interaction with antithrombin (AT): heparin binds to a specific pentasaccharide sequence on AT, inducing a conformational change that accelerates the rate of AT-mediated inhibition of thrombin (factor IIa), factor Xa, and other serine proteases by approximately 1,000-fold. An important structural requirement distinguishes the anti-IIa and anti-Xa activities: inhibition of thrombin requires the formation of a ternary complex in which heparin simultaneously bridges AT and thrombin, which necessitates a minimum heparin chain length of 18 saccharide units. In contrast, anti-Xa activity requires only the pentasaccharide sequence that binds AT; no bridging to the target protease is needed. This chain-length dependency is the fundamental principle that differentiates UFH from low-molecular-weight heparin and fondaparinux.

The pharmacokinetics of UFH are characterized by variability and unpredictability. It can be administered intravenously or subcutaneously, with subcutaneous bioavailability of only approximately 30%. The half-life is dose-dependent, ranging from 1 to 2 hours at therapeutic doses, and clearance occurs through both the reticuloendothelial system and renal elimination. UFH is not dialyzable. Weight-based dosing for VTE treatment typically employs an initial bolus of 80 IU/kg followed by a continuous infusion at 18 IU/kg per hour, with dose adjustments guided by monitoring.

Monitoring of UFH can be performed using either the activated partial thromboplastin time (aPTT), with a target range of 1.5 to 2.5 times the control value, or the anti-Xa chromogenic assay, with a target range of 0.3 to 0.7 IU/mL. The anti-Xa assay is increasingly recognized as the more reliable monitoring method because it is unaffected by variables that confound the aPTT, including lupus anticoagulant, elevated factor VIII levels, and baseline aPTT abnormalities. Reversal of UFH is accomplished with protamine sulfate, dosed at 1 mg per 100 IU of heparin administered within the preceding 2 to 3 hours. Protamine completely neutralizes the anti-IIa activity of UFH but only partially reverses its anti-Xa activity (approximately 60%).

The advantages of UFH include its short half-life (facilitating rapid titration and cessation before procedures), complete reversibility with protamine, safety in severe renal failure (unlike renally cleared alternatives), and its preferred role in massive PE where thrombolysis may be required. Its disadvantages include the requirement for intravenous infusion, frequent laboratory monitoring, unpredictable pharmacokinetics necessitating dose adjustments, and the risk of heparin-induced thrombocytopenia (HIT) at approximately 1 to 5%.

Low-Molecular-Weight Heparin (LMWH)

Low-molecular-weight heparins are produced by controlled depolymerization of UFH, yielding shorter chain fragments with a mean molecular weight of 4,000 to 5,000 daltons compared to 12,000 to 15,000 daltons for UFH. This reduction in chain length has profound pharmacologic consequences. Because the majority of LMWH chains are shorter than the 18 saccharide units required to bridge AT and thrombin, LMWH exhibits predominantly anti-Xa activity, with anti-Xa to anti-IIa ratios ranging from 2:1 to 4:1 depending on the specific preparation.

The pharmacokinetic profile of LMWH is markedly superior to that of UFH. Subcutaneous bioavailability is approximately 90%, providing predictable dose-response relationships that eliminate the need for routine monitoring in most patients. Peak anti-Xa levels are achieved 3 to 5 hours after injection, and the half-life of 3 to 6 hours permits convenient once- or twice-daily dosing. LMWH is cleared predominantly through the kidneys, which necessitates dose adjustment or avoidance in patients with significant renal impairment (creatinine clearance below 30 mL/min).

The principal agents include enoxaparin, dosed at 1 mg/kg subcutaneously every 12 hours for VTE treatment or 40 mg subcutaneously once daily for prophylaxis, with dose reduction to 1 mg/kg once daily when creatinine clearance falls below 30 mL/min; dalteparin at 200 IU/kg subcutaneously once daily for treatment or 5,000 IU once daily for prophylaxis; and tinzaparin at 175 IU/kg subcutaneously once daily. Monitoring with anti-Xa levels is generally not required but should be performed in specific populations including patients with obesity exceeding 150 kg, extremes of body weight, renal insufficiency, and pregnancy. For enoxaparin administered twice daily, the target peak anti-Xa level (measured 4 hours post-dose) is 0.6 to 1.0 IU/mL. Protamine provides only partial reversal of LMWH, neutralizing approximately 60% of anti-Xa activity while fully reversing the anti-IIa component. The risk of HIT is lower with LMWH than with UFH, at approximately 0.1 to 0.5%, though platelet monitoring remains prudent.

Fondaparinux (Arixtra)

Fondaparinux is a synthetic pentasaccharide that represents the minimal AT-binding sequence of heparin. As a selective, indirect factor Xa inhibitor acting exclusively through AT, it possesses no anti-IIa activity whatsoever. Administered subcutaneously, fondaparinux has a long half-life of 17 to 21 hours permitting once-daily dosing and is cleared entirely by the kidneys, contraindicating its use when creatinine clearance falls below 30 mL/min. Weight-based dosing for VTE treatment employs 5 mg for patients under 50 kg, 7.5 mg for those weighing 50 to 100 kg, and 10 mg for those above 100 kg, while prophylactic dosing is 2.5 mg subcutaneously once daily.

A critical pharmacologic distinction of fondaparinux is that it does not bind platelet factor 4 and therefore does not cause heparin-induced thrombocytopenia, making it a valuable option for anticoagulation in patients with a history of HIT, though this use is off-label and carries the caveat of its long half-life and lack of a specific reversal agent. Recombinant activated factor VII (rFVIIa) may be considered in the setting of life-threatening bleeding, but evidence for its efficacy in this context is limited.

<image>A pharmacology comparison diagram of heparin-based anticoagulants. Show three columns for UFH, LMWH (enoxaparin), and fondaparinux. For each, illustrate: the molecular structure (UFH as long heterogeneous chains, LMWH as shorter chains, fondaparinux as the minimal pentasaccharide), mechanism (UFH forming ternary complex with AT+thrombin for anti-IIa, plus AT+Xa for anti-Xa; LMWH preferentially anti-Xa with shorter chains unable to bridge thrombin; fondaparinux exclusively anti-Xa via AT conformational change). Include a comparison table below with: route, bioavailability, half-life, monitoring method, reversal agent, HIT risk, renal clearance, and typical dosing. Use molecular diagrams showing the AT-heparin-thrombin ternary complex with chain length dependency. Medical pharmacology textbook style.</image>

Direct Oral Anticoagulants (DOACs)

Factor Xa Inhibitors

Rivaroxaban (Xarelto)

Rivaroxaban is a direct factor Xa inhibitor that binds to the active site of both free and prothrombinase-bound factor Xa without requiring antithrombin as a cofactor. It is administered orally, with bioavailability of 80 to 100% for the 15 mg and 20 mg doses, provided they are taken with food. This food requirement is clinically critical: absorption of rivaroxaban decreases by approximately 40% when the higher doses are taken without food, potentially resulting in subtherapeutic drug levels and treatment failure. The half-life ranges from 5 to 9 hours in younger adults to 11 to 13 hours in the elderly. Metabolism is approximately two-thirds hepatic (primarily via CYP3A4 and CYP2J2) and one-third renal excretion of unchanged drug.

Dosing for VTE treatment follows a lead-in strategy of 15 mg twice daily for 21 days followed by 20 mg once daily with food. For extended VTE prevention, rivaroxaban 10 mg daily (EINSTEIN CHOICE) provides effective secondary prophylaxis with bleeding rates comparable to aspirin. For atrial fibrillation, the dose is 20 mg daily with food for patients with creatinine clearance above 50 mL/min, reduced to 15 mg daily for creatinine clearance of 15 to 50 mL/min. Clinically significant drug interactions occur with strong combined CYP3A4 and P-glycoprotein (P-gp) inhibitors (ketoconazole, ritonavir) and inducers (rifampin), which should be avoided or managed with appropriate dose adjustments.

Apixaban (Eliquis)

Apixaban is a direct factor Xa inhibitor administered orally twice daily, with a bioavailability of approximately 50% that is notably independent of food intake, eliminating the food-timing concerns associated with rivaroxaban. The half-life is approximately 12 hours, providing relatively stable drug levels with twice-daily dosing. A distinguishing pharmacokinetic feature of apixaban is its minimal renal clearance, with only 27% of the drug eliminated through the kidneys and the remainder metabolized hepatically, primarily via CYP3A4. This makes apixaban the safest DOAC for use in patients with chronic kidney disease.

For VTE treatment, apixaban employs a 7-day lead-in of 10 mg twice daily followed by maintenance dosing of 5 mg twice daily. Extended VTE prevention uses a reduced dose of 2.5 mg twice daily based on the AMPLIFY-EXT trial. For atrial fibrillation, the standard dose is 5 mg twice daily, with dose reduction to 2.5 mg twice daily for patients meeting at least two of the following criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or greater. Among the DOACs, apixaban has demonstrated the lowest rate of gastrointestinal bleeding across clinical trials, an important consideration for patients at elevated risk for gastrointestinal hemorrhage.

Edoxaban (Savaysa)

Edoxaban is a once-daily direct factor Xa inhibitor with a bioavailability of 62% that is independent of food intake. The half-life ranges from 10 to 14 hours, and approximately 50% of the drug is cleared renally. For VTE treatment, edoxaban is dosed at 60 mg daily but requires a minimum 5-day lead-in period of parenteral anticoagulation with heparin. The dose is reduced to 30 mg daily for patients with creatinine clearance of 15 to 50 mL/min, body weight of 60 kg or less, or concurrent use of P-glycoprotein inhibitors. A unique and counterintuitive characteristic of edoxaban in the atrial fibrillation indication is that it is contraindicated in patients with creatinine clearance exceeding 95 mL/min, as the ENGAGE AF-TIMI 48 trial demonstrated reduced efficacy compared to warfarin in this subgroup, likely due to increased renal clearance resulting in lower drug exposure.

Direct Thrombin Inhibitor

Dabigatran (Pradaxa)

Dabigatran etexilate is an orally administered prodrug that is converted to dabigatran, a direct, reversible inhibitor of both free and clot-bound thrombin (factor IIa). It is unique among the DOACs in its mechanism of action and carries several distinctive pharmacokinetic properties. Bioavailability is notably low at 3 to 7%, and absorption requires an acidic environment, which is facilitated by the tartaric acid core incorporated into each capsule. This tartaric acid component is also responsible for the dyspepsia that occurs in a significant proportion of patients. The half-life is 12 to 17 hours, and 80% of the drug is cleared renally, making dabigatran the most susceptible DOAC to accumulation in renal impairment.

Dosing for VTE treatment is 150 mg twice daily following at least 5 days of initial parenteral anticoagulation. For atrial fibrillation, the dose is 150 mg twice daily, reduced to 75 mg twice daily for patients with creatinine clearance of 15 to 30 mL/min in US labeling. A unique practical consideration is that dabigatran capsules are moisture-sensitive and must be stored in their original container; capsules removed from the blister pack and stored in pill organizers degrade within 4 months. Drug interactions are primarily mediated through P-glycoprotein, with dronedarone and cyclosporine requiring dose reduction or avoidance, and P-gp inducers such as rifampin contraindicating use. A unique advantage of dabigatran among the DOACs is that it can be removed by hemodialysis, providing an additional option for drug clearance in the settings of overdose or the need for emergent surgery.

DOAC Monitoring

A defining advantage of DOACs over warfarin is that routine coagulation monitoring is not required. However, specific clinical scenarios do require assessment of DOAC drug levels, including overdose, major bleeding, urgent preoperative evaluation, extremes of body weight or renal function, and suspected non-adherence. For the factor Xa inhibitors (rivaroxaban, apixaban, edoxaban), the anti-Xa chromogenic assay calibrated with drug-specific standards is the most accurate method for quantifying drug levels. For dabigatran, the dilute thrombin time (dTT) or ecarin clotting time provides quantitative measurement of drug concentration.

Conventional coagulation tests are unreliable for DOAC assessment. The PT/INR is insensitive to apixaban and shows variable prolongation with rivaroxaban, making it unsuitable for monitoring either agent. The aPTT is prolonged by dabigatran but in a non-linear fashion; however, a normal aPTT can effectively exclude supratherapeutic dabigatran levels, providing a useful qualitative screen.

DOAC Reversal

Idarucizumab (Praxbind) - Dabigatran-Specific

Idarucizumab is a humanized monoclonal antibody fragment (Fab) that binds dabigatran with approximately 350 times higher affinity than thrombin, effectively sequestering the drug and preventing it from inhibiting thrombin. The dose is 5 g intravenously, administered as two 2.5 g vials over 5 to 10 minutes. The RE-VERSE AD trial demonstrated that idarucizumab normalized the dilute thrombin time within minutes in 98% of patients presenting with either uncontrolled bleeding or the need for urgent surgery. Reversal is essentially complete within minutes of administration, though the effects may wane at 12 to 24 hours if circulating dabigatran redistributes from extravascular compartments, necessitating clinical vigilance and consideration of re-dosing.

Andexanet Alfa (Andexxa) - Factor Xa Inhibitor Reversal

Andexanet alfa is a recombinant modified factor Xa molecule that has been rendered catalytically inactive but retains the ability to bind and sequester factor Xa inhibitors, functioning as a molecular decoy. Dosing follows a two-tier schema: a low-dose regimen (400 mg bolus followed by a 4 mg/min infusion for 120 minutes) is used for patients who last took apixaban 5 mg or rivaroxaban 10 mg or less within the preceding 8 hours, while a high-dose regimen (800 mg bolus followed by an 8 mg/min infusion for 120 minutes) is used for all other scenarios. The ANNEXA-4 trial demonstrated effective anti-Xa activity reduction with good or excellent hemostasis achieved in 82% of treated patients.

Several important limitations temper enthusiasm for andexanet alfa. It is extremely expensive, costing $25,000 to $50,000 per treatment. It carries an approximately 10% rate of thrombotic events within 30 days, likely related to its mechanism of binding endogenous factor Xa pathway components. Its half-life is relatively short, and the anticoagulant effect may return as the drug is cleared, requiring ongoing monitoring. It reverses fondaparinux and LMWH in vitro, though clinical data for these indications are limited. For many DOAC-associated bleeding events, supportive care with tranexamic acid, prothrombin complex concentrate, and simple time (allowing drug clearance given the relatively short half-lives of DOACs) is often sufficient, and specific reversal may not be necessary.

Prothrombin Complex Concentrate (PCC)

Four-factor PCC (Kcentra/Beriplex), containing factors II, VII, IX, X along with proteins C and S, serves as a non-specific reversal agent for DOAC-associated major bleeding when specific reversal agents are unavailable or deemed unnecessary. The dose is 25 to 50 IU/kg administered intravenously. Evidence supporting PCC for DOAC reversal is primarily derived from observational studies and healthy volunteer pharmacodynamic studies rather than randomized clinical trials. Activated PCC (FEIBA) represents an alternative that may provide greater hemostatic efficacy but carries a commensurately higher thrombotic risk.

<image>A DOAC comparison table and reversal agent diagram. Top section: a comparison table of four DOACs (rivaroxaban, apixaban, edoxaban, dabigatran) with rows for: target (Xa vs. IIa), bioavailability, food requirement, half-life, renal clearance percentage, dosing for VTE and AF, key drug interactions, and whether dialyzable. Use color coding to highlight key differences. Bottom section: a reversal strategy flowchart. Show "DOAC-associated major bleeding" at the top. Branch into: (1) dabigatran → idarucizumab 5g IV (specific reversal) or hemodialysis; (2) factor Xa inhibitor → andexanet alfa (specific reversal, with low-dose vs. high-dose criteria) OR 4-factor PCC 25-50 IU/kg (non-specific) + TXA. Include time-to-effect for each reversal strategy. For all DOACs, show supportive measures: hold drug, TXA, mechanical hemostasis, activated charcoal if <2 hours post-ingestion. Medical pharmacology reference card style.</image>

Warfarin (Brief Review for Comparison)

Key Points

Warfarin, a vitamin K antagonist, inhibits the vitamin K-dependent gamma-carboxylation of coagulation factors II, VII, IX, and X as well as the anticoagulant proteins C and S. Because the full anticoagulant effect of warfarin depends on the clearance of previously carboxylated factor II, which has a half-life of approximately 72 hours, the onset of full therapeutic anticoagulation requires 5 to 7 days even though the INR may rise earlier due to the shorter half-life of factor VII. This delayed onset necessitates an overlap period with parenteral anticoagulation when treating acute thrombosis. Monitoring with the INR is required, with targets of 2.0 to 3.0 for most indications and 2.5 to 3.5 for mechanical mitral valves. Warfarin is notoriously difficult to manage due to its numerous drug-food interactions and its narrow therapeutic window. Pharmacogenomic variation in CYP2C9 (which metabolizes warfarin) and VKORC1 (the target enzyme) influences dose requirements.

Reversal of warfarin-associated bleeding employs vitamin K 10 mg intravenously combined with 4-factor PCC at 25 to 50 IU/kg for major hemorrhage, or vitamin K alone for asymptomatic INR elevation. Two critical indications remain where warfarin is preferred over DOACs: mechanical heart valves (DOACs are contraindicated following the RE-ALIGN trial, which was terminated early due to excess thromboembolic and bleeding events with dabigatran) and antiphospholipid syndrome, particularly triple-positive APS (the TRAPS trial demonstrated that rivaroxaban was inferior to warfarin, with significantly more thrombotic events).

Perioperative Management of Anticoagulation

DOAC Interruption

The perioperative management of DOACs has been simplified by the PAUSE study, which validated a standardized interruption protocol that eliminated routine bridging anticoagulation and demonstrated low rates of both bleeding and thromboembolism. For procedures with low bleeding risk, DOACs are held for 1 day before and 1 day after the procedure (effectively skipping 1 dose for twice-daily drugs and 2 doses for once-daily drugs). For procedures with high bleeding risk, DOACs are held for 2 days before and 2 days after. Patients with renal impairment (creatinine clearance 15 to 30 mL/min) require extended interruption intervals: 3 to 4 days for dabigatran, reflecting its 80% renal clearance, and 2 to 3 days for the factor Xa inhibitors. The BRIDGE trial, although conducted in warfarin-treated patients, established the principle that bridging anticoagulation with heparin increases bleeding without reducing thromboembolism, and this principle applies equally to DOAC interruption.

Warfarin Interruption

For patients on warfarin requiring elective procedures, the drug is stopped 5 days before the procedure and the INR is checked the day prior to ensure adequate decline. Bridging with LMWH is not recommended for most patients based on the BRIDGE trial results. Bridging should be considered only for patients at the highest thrombotic risk, specifically those with certain mechanical heart valves or very recent VTE within the preceding 3 months.

Key Clinical Pearls

• Rivaroxaban 15 mg and 20 mg MUST be taken with food (absorption drops 40% without food); apixaban is food-independent
• Apixaban has the lowest renal clearance (27%) among DOACs and is the safest choice for patients with CKD
• Dabigatran is the only DOAC that can be removed by hemodialysis; valuable in overdose or when urgent surgery is needed
• Warfarin remains required for mechanical heart valves and triple-positive antiphospholipid syndrome; DOACs are contraindicated in these settings
• Bridging anticoagulation is NOT recommended when interrupting DOACs or warfarin perioperatively (BRIDGE and PAUSE trials); it increases bleeding without reducing thromboembolism
• Andexanet alfa is expensive and carries a 10% thrombotic risk; 4-factor PCC is a reasonable alternative for factor Xa inhibitor reversal in many clinical scenarios
• Anti-Xa levels with drug-specific calibrators are the most accurate way to assess DOAC levels when clinical decisions depend on drug presence

References

1. Burnett AE, et al. Guidance for the practical management of the direct oral anticoagulants (DOACs). J Thromb Thrombolysis. 2016;41(1):206-232.
2. Douketis JD, et al. Perioperative management of patients receiving direct oral anticoagulants (PAUSE). JAMA Intern Med. 2019;179(11):1469-1478.
3. Connolly SJ, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors (ANNEXA-4). N Engl J Med. 2019;380(14):1326-1335.
4. Pollack CV Jr, et al. Idarucizumab for dabigatran reversal (RE-VERSE AD). N Engl J Med. 2015;373(6):511-520.
5. Douketis JD, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation (BRIDGE). N Engl J Med. 2015;373(9):823-833.

Read this lecture as Markdown